KR20200014406A - Ii형 진성 당뇨병을 갖는 환자에서 심혈관 사건을 감소시키거나 예방하는 방법 - Google Patents
Ii형 진성 당뇨병을 갖는 환자에서 심혈관 사건을 감소시키거나 예방하는 방법 Download PDFInfo
- Publication number
- KR20200014406A KR20200014406A KR1020207000103A KR20207000103A KR20200014406A KR 20200014406 A KR20200014406 A KR 20200014406A KR 1020207000103 A KR1020207000103 A KR 1020207000103A KR 20207000103 A KR20207000103 A KR 20207000103A KR 20200014406 A KR20200014406 A KR 20200014406A
- Authority
- KR
- South Korea
- Prior art keywords
- cardiovascular
- disease
- patient
- history
- nonfatal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000007211 cardiovascular event Effects 0.000 title claims description 74
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims description 45
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 102
- 238000000034 method Methods 0.000 claims abstract description 71
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 70
- 230000034994 death Effects 0.000 claims description 60
- 231100000517 death Toxicity 0.000 claims description 60
- 206010019280 Heart failures Diseases 0.000 claims description 49
- 208000006011 Stroke Diseases 0.000 claims description 44
- 230000002411 adverse Effects 0.000 claims description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 43
- 208000010125 myocardial infarction Diseases 0.000 claims description 40
- 208000024891 symptom Diseases 0.000 claims description 30
- 208000008589 Obesity Diseases 0.000 claims description 29
- 235000020824 obesity Nutrition 0.000 claims description 29
- 238000012360 testing method Methods 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 24
- 206010020772 Hypertension Diseases 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 23
- 230000002265 prevention Effects 0.000 claims description 20
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 19
- 230000009467 reduction Effects 0.000 claims description 18
- 206010027525 Microalbuminuria Diseases 0.000 claims description 15
- 206010002383 Angina Pectoris Diseases 0.000 claims description 14
- 230000000747 cardiac effect Effects 0.000 claims description 14
- 230000000302 ischemic effect Effects 0.000 claims description 13
- 208000001871 Tachycardia Diseases 0.000 claims description 10
- 206010003119 arrhythmia Diseases 0.000 claims description 10
- 230000006794 tachycardia Effects 0.000 claims description 10
- 206010002388 Angina unstable Diseases 0.000 claims description 9
- 206010014486 Elevated triglycerides Diseases 0.000 claims description 9
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 9
- 208000007814 Unstable Angina Diseases 0.000 claims description 9
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 9
- 208000028867 ischemia Diseases 0.000 claims description 7
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 6
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 6
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 6
- 208000019553 vascular disease Diseases 0.000 claims description 6
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 5
- 230000006793 arrhythmia Effects 0.000 claims description 5
- 238000007887 coronary angioplasty Methods 0.000 claims description 5
- 230000001747 exhibiting effect Effects 0.000 claims description 5
- 208000003663 ventricular fibrillation Diseases 0.000 claims description 5
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 4
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims description 4
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 4
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 210000003423 ankle Anatomy 0.000 claims description 3
- 208000015210 hypertensive heart disease Diseases 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 206010002329 Aneurysm Diseases 0.000 claims description 2
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 2
- 210000001367 artery Anatomy 0.000 claims description 2
- 238000007675 cardiac surgery Methods 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 230000000652 homosexual effect Effects 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 210000003141 lower extremity Anatomy 0.000 claims description 2
- 230000036262 stenosis Effects 0.000 claims description 2
- 208000037804 stenosis Diseases 0.000 claims description 2
- 230000002889 sympathetic effect Effects 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 description 47
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 46
- 210000004369 blood Anatomy 0.000 description 37
- 239000008280 blood Substances 0.000 description 37
- 206010012601 diabetes mellitus Diseases 0.000 description 24
- 208000035475 disorder Diseases 0.000 description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 239000000902 placebo Substances 0.000 description 20
- 229940068196 placebo Drugs 0.000 description 20
- 210000003734 kidney Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 206010001580 Albuminuria Diseases 0.000 description 14
- 210000002216 heart Anatomy 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- 206010022489 Insulin Resistance Diseases 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 208000029078 coronary artery disease Diseases 0.000 description 12
- 230000035488 systolic blood pressure Effects 0.000 description 12
- 108010010234 HDL Lipoproteins Proteins 0.000 description 10
- 102000015779 HDL Lipoproteins Human genes 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000036772 blood pressure Effects 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 230000035487 diastolic blood pressure Effects 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 239000003937 drug carrier Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 102000007330 LDL Lipoproteins Human genes 0.000 description 8
- 108010007622 LDL Lipoproteins Proteins 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 230000000004 hemodynamic effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 230000024924 glomerular filtration Effects 0.000 description 7
- 208000019622 heart disease Diseases 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 208000017169 kidney disease Diseases 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 201000009104 prediabetes syndrome Diseases 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 description 5
- 206010033307 Overweight Diseases 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000001473 noxious effect Effects 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000000391 smoking effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 4
- 206010014476 Elevated cholesterol Diseases 0.000 description 4
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 description 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 4
- 208000001280 Prediabetic State Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229960001713 canagliflozin Drugs 0.000 description 4
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 208000033679 diabetic kidney disease Diseases 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 201000008980 hyperinsulinism Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000000291 postprandial effect Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 206010047302 ventricular tachycardia Diseases 0.000 description 4
- 208000004611 Abdominal Obesity Diseases 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 206010007687 Carotid artery stenosis Diseases 0.000 description 3
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010072563 Peripheral artery stenosis Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 208000006170 carotid stenosis Diseases 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- -1 elixirs Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 108091005995 glycated hemoglobin Proteins 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000003709 heart valve Anatomy 0.000 description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 230000013878 renal filtration Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 206010049993 Cardiac death Diseases 0.000 description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 2
- 208000006029 Cardiomegaly Diseases 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 description 2
- 206010011906 Death Diseases 0.000 description 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100040918 Pro-glucagon Human genes 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 208000007474 aortic aneurysm Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003979 granulating agent Substances 0.000 description 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002642 intravenous therapy Methods 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010001029 Acute pulmonary oedema Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 241001553178 Arachis glabrata Species 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 208000004672 Cardiovascular Infections Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 206010011089 Coronary artery stenosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000002251 Dissecting Aneurysm Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010061340 Peripheral embolism Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 108091006269 SLC5A2 Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000007888 Sinus Tachycardia Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 102000058081 Sodium-Glucose Transporter 2 Human genes 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010049514 Traumatic fracture Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 206010002895 aortic dissection Diseases 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 206010003668 atrial tachycardia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002665 bowman capsule Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003684 cardiac depression Effects 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008162 cooking oil Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000005086 glomerual capillary Anatomy 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 108010049074 hemoglobin B Proteins 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000011661 metabolic syndrome X Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518547P | 2017-06-12 | 2017-06-12 | |
| US62/518,547 | 2017-06-12 | ||
| PCT/IB2018/054208 WO2018229630A1 (en) | 2017-06-12 | 2018-06-11 | Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200014406A true KR20200014406A (ko) | 2020-02-10 |
Family
ID=62916717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207000103A Ceased KR20200014406A (ko) | 2017-06-12 | 2018-06-11 | Ii형 진성 당뇨병을 갖는 환자에서 심혈관 사건을 감소시키거나 예방하는 방법 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20180353470A1 (https=) |
| EP (1) | EP3638250A1 (https=) |
| JP (2) | JP2020523408A (https=) |
| KR (1) | KR20200014406A (https=) |
| CN (1) | CN110740735A (https=) |
| AU (1) | AU2018283781B2 (https=) |
| BR (1) | BR112019026120A2 (https=) |
| CA (1) | CA3066874A1 (https=) |
| CO (1) | CO2019013940A2 (https=) |
| EA (1) | EA202090028A1 (https=) |
| IL (1) | IL271100A (https=) |
| MX (1) | MX2019014988A (https=) |
| TW (1) | TWI835735B (https=) |
| UA (1) | UA127987C2 (https=) |
| WO (1) | WO2018229630A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230046951A1 (en) * | 2021-08-03 | 2023-02-16 | National Chengchi University | System and method for assessing risk of type 2 mellitus diabetes complications |
| CN117085009B (zh) * | 2023-10-20 | 2024-01-30 | 首都医科大学附属北京天坛医院 | 卡格列净对急性缺血性卒中的治疗作用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2531660T3 (es) | 2003-08-01 | 2015-03-18 | Mitsubishi Tanabe Pharma Corporation | Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| NO2385374T3 (https=) * | 2010-05-05 | 2014-06-07 | ||
| US20130052266A1 (en) * | 2010-05-11 | 2013-02-28 | Mitsubishi Tanabe Pharma Corporation | TABLETS CONTAINING A 1-(beta-D-GLUCOPYRANOSYL)-3-(PHENYLTHIENYLMETHYL)BENZENE COMPOUND |
| CA2812016A1 (en) * | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20160000816A1 (en) * | 2013-04-05 | 2016-01-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| AU2015210898A1 (en) * | 2014-01-31 | 2016-07-28 | Janssen Pharmaceutica Nv | Methods for the treatment and prevention of renal disorders and fatty liver disorders |
| US20170071970A1 (en) * | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
-
2018
- 2018-06-08 TW TW107119774A patent/TWI835735B/zh not_active IP Right Cessation
- 2018-06-11 KR KR1020207000103A patent/KR20200014406A/ko not_active Ceased
- 2018-06-11 US US16/004,607 patent/US20180353470A1/en not_active Abandoned
- 2018-06-11 AU AU2018283781A patent/AU2018283781B2/en not_active Ceased
- 2018-06-11 CA CA3066874A patent/CA3066874A1/en active Pending
- 2018-06-11 BR BR112019026120-6A patent/BR112019026120A2/pt not_active Application Discontinuation
- 2018-06-11 JP JP2020517619A patent/JP2020523408A/ja active Pending
- 2018-06-11 UA UAA202000168A patent/UA127987C2/uk unknown
- 2018-06-11 WO PCT/IB2018/054208 patent/WO2018229630A1/en not_active Ceased
- 2018-06-11 MX MX2019014988A patent/MX2019014988A/es unknown
- 2018-06-11 EP EP18740894.3A patent/EP3638250A1/en not_active Withdrawn
- 2018-06-11 CN CN201880039211.2A patent/CN110740735A/zh active Pending
- 2018-06-11 EA EA202090028A patent/EA202090028A1/ru unknown
-
2019
- 2019-12-02 IL IL271100A patent/IL271100A/en unknown
- 2019-12-11 CO CONC2019/0013940A patent/CO2019013940A2/es unknown
-
2020
- 2020-09-15 US US17/021,370 patent/US20210000792A1/en not_active Abandoned
-
2023
- 2023-05-10 JP JP2023077544A patent/JP2023113644A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| TWI835735B (zh) | 2024-03-21 |
| JP2023113644A (ja) | 2023-08-16 |
| EA202090028A1 (ru) | 2020-04-03 |
| IL271100A (en) | 2020-01-30 |
| CO2019013940A2 (es) | 2020-01-17 |
| EP3638250A1 (en) | 2020-04-22 |
| CA3066874A1 (en) | 2018-12-20 |
| MX2019014988A (es) | 2020-08-06 |
| JP2020523408A (ja) | 2020-08-06 |
| BR112019026120A2 (pt) | 2020-07-07 |
| US20210000792A1 (en) | 2021-01-07 |
| US20180353470A1 (en) | 2018-12-13 |
| AU2018283781A1 (en) | 2019-12-19 |
| CN110740735A (zh) | 2020-01-31 |
| AU2018283781B2 (en) | 2023-09-28 |
| UA127987C2 (uk) | 2024-03-06 |
| WO2018229630A1 (en) | 2018-12-20 |
| TW201904584A (zh) | 2019-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7843308B2 (ja) | エンパグリフロジンを含む医薬組成物及びその使用 | |
| Li–Sheng | 2018 Chinese guidelines for prevention and treatment of hypertension—a report of the revision committee of Chinese guidelines for prevention and treatment of hypertension | |
| Kimura et al. | JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome | |
| Hunt et al. | 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation | |
| Parrinello et al. | Long-term effects of dietary sodium intake on cytokines and neurohormonal activation in patients with recently compensated congestive heart failure | |
| Sakai et al. | Effects of sodium-glucose cotransporter 2 inhibitor on vascular endothelial and diastolic function in heart failure with preserved ejection fraction―novel prospective cohort study― | |
| CN110075301A (zh) | 依帕列净的治疗用途 | |
| JP2023113644A (ja) | ２型糖尿病の患者における心血管イベントの低減又は予防方法 | |
| US20250152671A1 (en) | Medical composition for treating patients exhibiting cardiac decompensation | |
| Wu et al. | SGLT2 inhibitors: new hope for the treatment of acute myocardial infarction? | |
| Li et al. | New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure | |
| JP2020523408A5 (https=) | ||
| Nassiri et al. | Effects of geranylgeranylacetone on diastolic and microvascular function in patients with heart failure with a preserved ejection fraction: A phase 2, randomized, placebo‐controlled, crossover trial | |
| Maung et al. | Hypokalaemic rhabdomyolysis as initial presentation of primary aldosteronism | |
| HK40021204A (en) | Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus | |
| Ruxer et al. | ``White coat hypertension''in type 2 diabetic patients | |
| Afshinnia et al. | Approach to Chronic Kidney Disease in the Diabetic Patient | |
| Hasselbalch et al. | P1745 routine blood tests are strong predictors of mortality among patients with suspected heart disease in the emergency department | |
| Mamedov et al. | Cardiovascular diseases and risk | |
| Schindler et al. | Improvement of coronary vascular dysfunction in type 2 diabetic patients with euglycemic control | |
| Cicero et al. | [OP. 1A. 10] CIRCULATING LEVELS OF PCSK9 AND ARTERIAL STIFFNESS IN A LARGE POPULATION SAMPLE: DATA FROM THE BRISIGHELLA HEART STUDY | |
| Paulo et al. | PROGNOSTIC VALUE OF THORACIC FLUID CONTENT AFTER AN EPISODE OF ACUTE HEART FAILURE | |
| Strazynska et al. | THE APELIN CONCENTRATION IN YOUNG HYPERTENSIVE PATIENTS WITH EXCEEDED BODY WEIGHT: PP. 29.403 | |
| Aksnes et al. | PREDICTORS OF CARDIAC MORBIDITY IN DIABETIC, NEW-ONSET DIABETIC AND NON-DIABETIC HIGH-RISK HYPERTENSIVE PATIENTS: THE VALUE TRIAL: 5A. 03 | |
| Quiles et al. | FACTORS PROTECTING OR FAVOURING FEAR IN CARDIAC HEART FAILURE PATIENTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20200102 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210603 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230818 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20240228 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20230818 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |